Cargando…

Nationwide survey on current treatments for IgA nephropathy in Japan

BACKGROUND: A wide variety of treatments, including tonsillectomy and steroid pulse therapy (TSP), are performed for the various stages of IgA nephropathy (IgAN) in Japan. However, the current status of treatments for IgAN patients in Japan is still unclear. The objective of the present study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuzaki, Keiichi, Suzuki, Yusuke, Nakata, Junichiro, Sakamoto, Naoko, Horikoshi, Satoshi, Kawamura, Tetsuya, Matsuo, Seiichi, Tomino, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889220/
https://www.ncbi.nlm.nih.gov/pubmed/23519367
http://dx.doi.org/10.1007/s10157-013-0779-7
_version_ 1782299166228086784
author Matsuzaki, Keiichi
Suzuki, Yusuke
Nakata, Junichiro
Sakamoto, Naoko
Horikoshi, Satoshi
Kawamura, Tetsuya
Matsuo, Seiichi
Tomino, Yasuhiko
author_facet Matsuzaki, Keiichi
Suzuki, Yusuke
Nakata, Junichiro
Sakamoto, Naoko
Horikoshi, Satoshi
Kawamura, Tetsuya
Matsuo, Seiichi
Tomino, Yasuhiko
author_sort Matsuzaki, Keiichi
collection PubMed
description BACKGROUND: A wide variety of treatments, including tonsillectomy and steroid pulse therapy (TSP), are performed for the various stages of IgA nephropathy (IgAN) in Japan. However, the current status of treatments for IgAN patients in Japan is still unclear. The objective of the present study was to investigate the current status of treatments for IgAN patients. METHODS: A nationwide survey was conducted in 2008 by sending questionnaires to the 1,194 teaching hospitals of the Japanese Society of Nephrology (JSN) via Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health, Labour and Welfare of Japan. RESULTS: Among the total 376 hospitals (31.4 %) that responded, 188 hospitals (66.2 % in the internal medicine departments) performed TSP, out of which 137 hospitals (61.4 %) had begun to perform TSP in the period from 2004 to 2008. The following two major steroid pulse protocols in TSP were used: (1) three cycles over 3 consecutive weeks and (2) three cycles every 2 months. Approximately 68 % of pediatric hospitals (68 hospitals) performed combination therapy with prednisolone, azathioprine, heparin-warfarin and dipyridamole. The clinical remission rates for hematuria and proteinuria after TSP tended to be higher than those following other corticosteroid therapies. Almost all hospitals prescribed antiplatelet agents and renin angiotensin system inhibitor (RAS-I). CONCLUSION: In addition to popular treatments such as antiplatelet agents and RAS-I, TSP is becoming a standard treatment for adult IgAN patients in Japan.
format Online
Article
Text
id pubmed-3889220
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-38892202014-01-14 Nationwide survey on current treatments for IgA nephropathy in Japan Matsuzaki, Keiichi Suzuki, Yusuke Nakata, Junichiro Sakamoto, Naoko Horikoshi, Satoshi Kawamura, Tetsuya Matsuo, Seiichi Tomino, Yasuhiko Clin Exp Nephrol Original Article BACKGROUND: A wide variety of treatments, including tonsillectomy and steroid pulse therapy (TSP), are performed for the various stages of IgA nephropathy (IgAN) in Japan. However, the current status of treatments for IgAN patients in Japan is still unclear. The objective of the present study was to investigate the current status of treatments for IgAN patients. METHODS: A nationwide survey was conducted in 2008 by sending questionnaires to the 1,194 teaching hospitals of the Japanese Society of Nephrology (JSN) via Progressive Renal Diseases Research, Research on intractable disease, from the Ministry of Health, Labour and Welfare of Japan. RESULTS: Among the total 376 hospitals (31.4 %) that responded, 188 hospitals (66.2 % in the internal medicine departments) performed TSP, out of which 137 hospitals (61.4 %) had begun to perform TSP in the period from 2004 to 2008. The following two major steroid pulse protocols in TSP were used: (1) three cycles over 3 consecutive weeks and (2) three cycles every 2 months. Approximately 68 % of pediatric hospitals (68 hospitals) performed combination therapy with prednisolone, azathioprine, heparin-warfarin and dipyridamole. The clinical remission rates for hematuria and proteinuria after TSP tended to be higher than those following other corticosteroid therapies. Almost all hospitals prescribed antiplatelet agents and renin angiotensin system inhibitor (RAS-I). CONCLUSION: In addition to popular treatments such as antiplatelet agents and RAS-I, TSP is becoming a standard treatment for adult IgAN patients in Japan. Springer Japan 2013-03-22 2013 /pmc/articles/PMC3889220/ /pubmed/23519367 http://dx.doi.org/10.1007/s10157-013-0779-7 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Matsuzaki, Keiichi
Suzuki, Yusuke
Nakata, Junichiro
Sakamoto, Naoko
Horikoshi, Satoshi
Kawamura, Tetsuya
Matsuo, Seiichi
Tomino, Yasuhiko
Nationwide survey on current treatments for IgA nephropathy in Japan
title Nationwide survey on current treatments for IgA nephropathy in Japan
title_full Nationwide survey on current treatments for IgA nephropathy in Japan
title_fullStr Nationwide survey on current treatments for IgA nephropathy in Japan
title_full_unstemmed Nationwide survey on current treatments for IgA nephropathy in Japan
title_short Nationwide survey on current treatments for IgA nephropathy in Japan
title_sort nationwide survey on current treatments for iga nephropathy in japan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889220/
https://www.ncbi.nlm.nih.gov/pubmed/23519367
http://dx.doi.org/10.1007/s10157-013-0779-7
work_keys_str_mv AT matsuzakikeiichi nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT suzukiyusuke nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT nakatajunichiro nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT sakamotonaoko nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT horikoshisatoshi nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT kawamuratetsuya nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT matsuoseiichi nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan
AT tominoyasuhiko nationwidesurveyoncurrenttreatmentsforiganephropathyinjapan